RE: Biokit9 Mar 2021 07:54
The deal today shows the increasing awareness and acceptance of Affimers. We are getting involved with top companies. The royalty model reminds me very much of ARM holdings, who designed superior microchips and licenced them out. Each year their designs were tweaked and improved, again top companies paid to use their specialised product.
Affimers are disruptive technology, they are patented. Each new deal will add to the "snowball effect" and Avacta will become the "go-to" company in a huge marketplace. All in my humble opinion, of course.